FIELD: medicine.
SUBSTANCE: invention concerns medicine, pharmaceutical industry, in particular to antiviral preparations and concerns creations of the new medicinal forms containing interferon. The liposomal antiviral treatment-and-prophylactic agent includes a recombinant human interferon alpha, phosphatidylcholine, cholesterol, alpha tocopherol, lactose, sodium chloride, twice-substituted sodium phosphate 12-water and mono-substituted sodium phosphate sodium 2-water, thus it represents a lyophilizate.
EFFECT: augmentation of a period of storage of the liposomal medicinal form where activity of the interferon alpha remains at constant level till 30 months.
1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ENCAPSULATED LYPOSOMAL ANTIVIRAL AGENT BASED ON HUMAN INTERFERON ALPHA-2b FOR VAGINAL APPLICATION | 2014 |
|
RU2552851C1 |
| METHOD FOR PRODUCING LIPID MIXTURE AND LIPOSOMAL ORAL ANTIVIRAL THERAPEUTIC AND PROPHYLACTIC AGENT USING SAID LIPID MIXTURE | 2020 |
|
RU2746320C1 |
| LIPOSOMAL ANTIVIRAL DRUG FOR ORAL USING | 1996 |
|
RU2123328C1 |
| LIPOSOMAL AGENT FOR TREATING CHRONIC ATROPHIC GASTRITIS | 2019 |
|
RU2724021C1 |
| METHOD FOR TREATING ACUTE HEPRETIC STOMATITIS IN CHILDREN | 2011 |
|
RU2444372C1 |
| METHOD OF PRODUCING LIPOSOMAL COSMETIC SERUM IN DRY LYOPHILIZED FORM FOR FACE, NECK AND CLEAVAGE SKIN CARE | 2023 |
|
RU2825130C1 |
| LIPOSOMAL INTERFERON INDUCER | 2004 |
|
RU2306936C2 |
| THERMOSTABLE COMPOSITION, HAVING ANTIVIRAL AND ANTIBACTERIAL ACTIVITY AND USE THEREOF | 2017 |
|
RU2718554C1 |
| ANTIVIRUS MEANS IN LIPOSOME FORM | 2000 |
|
RU2176518C1 |
| RECOMBINANT PLASMIDS pET32a-IFG144, PROVIDING INTERFERON GAMMA SYNTHESIS, BACTERIAL STRAIN ESCHERICHIA COLI JM109/pET32a-IFG144 - INTERFERON GAMMA PROTEIN PRODUCER, METHOD OF OBTAINING INTERFERON GAMMA AND MEDICINAL PRODUCT | 2022 |
|
RU2809358C1 |
